Gland Pharma Ltd — earnings calls

1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.

Q1 FY27 — transcript filed; not yet summarisedQ4 FY26

Gland Pharma reported Q4 FY26 consolidated revenue of INR17,428 million, up 22% year-on-year, with adjusted EBITDA of INR5,244 million at 30% margin and adjusted PAT of INR3,667 million at 21% margin. Full year FY26 revenue grew 14.5% to INR64,307 million, with the CDMO business contributing 46% of total revenue and growing 28%. Management attributed the quarter's performance to new product launches including Dalbavancin, GPO contract wins, capacity utilization improvements and steady contribution from the Cenexi subsidiary in France.